Collectively, therapeutic metabolic intervention in FLT3-ITD AML must extend beyond targeting glutamine catabolism or oxidative phosphorylation to encompass disruption of biosynthetic networks—encompassing nucleotide, membrane lipid, and amino acid production—through strategically designed combination approaches. Here, FLT3 is linked to acute myeloid leukemia.